These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25531694)

  • 1. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals.
    Morrow MP; Tebas P; Yan J; Ramirez L; Slager A; Kraynyak K; Diehl M; Shah D; Khan A; Lee J; Boyer J; Kim JJ; Sardesai NY; Weiner DB; Bagarazzi ML
    Mol Ther; 2015 Mar; 23(3):591-601. PubMed ID: 25531694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
    Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
    PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
    Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of HIV Tat DNA on regulating the immune response of HIV DNA vaccine in mice.
    Liu Y; Li F; Qi Z; Hao Y; Hong K; Liu Y; Cong Y; Shao Y
    Virol J; 2013 Sep; 10():297. PubMed ID: 24073803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
    Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
    PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
    Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
    Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
    Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
    Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.
    Roff SR; Sanou MP; Rathore MH; Levy JA; Yamamoto JK
    Hum Vaccin Immunother; 2015; 11(6):1540-56. PubMed ID: 25844718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
    Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
    Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost.
    Ake JA; Schuetz A; Pegu P; Wieczorek L; Eller MA; Kibuuka H; Sawe F; Maboko L; Polonis V; Karasavva N; Weiner D; Sekiziyivu A; Kosgei J; Missanga M; Kroidl A; Mann P; Ratto-Kim S; Anne Eller L; Earl P; Moss B; Dorsey-Spitz J; Milazzo M; Laissa Ouedraogo G; Rizvi F; Yan J; Khan AS; Peel S; Sardesai NY; Michael NL; Ngauy V; Marovich M; Robb ML
    J Infect Dis; 2017 Nov; 216(9):1080-1090. PubMed ID: 28968759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
    Harro CD; Robertson MN; Lally MA; O'Neill LD; Edupuganti S; Goepfert PA; Mulligan MJ; Priddy FH; Dubey SA; Kierstead LS; Sun X; Casimiro DR; DiNubile MJ; Shiver JW; Leavitt RY; Mehrotra DV;
    AIDS Res Hum Retroviruses; 2009 Jan; 25(1):103-14. PubMed ID: 19108693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen.
    Herath S; Le Heron A; Colloca S; Bergin P; Patterson S; Weber J; Tatoud R; Dickson G
    Vaccine; 2015 Dec; 33(51):7283-7289. PubMed ID: 26546736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice.
    Ajbani SP; Velhal SM; Kadam RB; Patel VV; Bandivdekar AH
    Int J Biol Macromol; 2015 Nov; 81():794-802. PubMed ID: 26361864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociated production of perforin, granzyme B, and IFN-gamma by HIV-specific CD8(+) cells in HIV infection.
    Kuerten S; Nowacki TM; Kleen TO; Asaad RJ; Lehmann PV; Tary-Lehmann M
    AIDS Res Hum Retroviruses; 2008 Jan; 24(1):62-71. PubMed ID: 18275349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of IFN-γ secretory ELISPOT based assay for screening of ADCC responses.
    Shete A; Suryawanshi P; Chavan C; Kulkarni A; Godbole S; Ghate M; Thakar M
    J Immunol Methods; 2017 Feb; 441():49-55. PubMed ID: 27923642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.